Open in another window Prostate malignancy (PCa) therapy typically involves administration of classical antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. demonstrates low mobile toxicity in PCa versions and dose reactive reduction of traditional antiandrogen-induced prostate particular antigen… Continue reading Open in another window Prostate malignancy (PCa) therapy typically involves administration